HomeChina: SPAC merger values YS Bio at US$834m

China: SPAC merger values YS Bio at US$834m

-

YS Biopharma, previously YishengBio, a leading human use rabies vaccine manufacturing company in China’s rabies vaccine market, is merging with blank cheque company Summit Healthcare Acquisition Corp. Upon closing, the combined company will…

Subscription required

This content is for Subscribers only. To access 4,800+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Nick Herbert
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Related Articles
More From Author

Subscription required

This content is for Subscribers only. To access 4,800+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?

Subscription required

This content is for Subscribers only. To access 4,800+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Advertisement

Related Resources

Related Events